Sonalleve MR-HIFU

Profound Medical to Release Second Quarter 2021 Financial Results on August 4 – Conference Call to Follow

Retrieved on: 
Thursday, July 15, 2021
Neoplasms, Sonalleve MR-HIFU, Uterine fibroid, Bone metastasis, Clinical medicine, Medicine, Medical ultrasonography, Surgical oncology

Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

Key Points: 
  • Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
  • Profound is commercializing TULSA-PRO, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control.
  • TULSA-PRO is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (FDA).
  • Profound is also commercializing Sonalleve, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

Profound Medical Announces Voting Results from the 2021 Annual Meeting of Shareholders and Management Changes

Retrieved on: 
Wednesday, May 19, 2021
Anatomy, Branches of biology, Neoplasms, Anatomical pathology, Medical physics, Gynaecological neoplasia, Uterine fibroid, Osteoid osteoma, Sonalleve MR-HIFU, Osteoma, Prostate cancer, XC2

TULSA-PRO\xc2\xae is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient\xe2\x80\x99s natural functional abilities.

Key Points: 
  • TULSA-PRO\xc2\xae is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient\xe2\x80\x99s natural functional abilities.
  • Sonalleve\xc2\xae has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma.
  • Such statements are based on the current expectations of the management of Profound.
  • Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended.

Profound Medical to Release First Quarter 2021 Financial Results on May 12 – Conference Call to Follow

Retrieved on: 
Wednesday, April 21, 2021
Anatomy, Branches of biology, Neoplasms, Anatomical pathology, Medical physics, Gynaecological neoplasia, Uterine fibroid, Osteoid osteoma, Sonalleve MR-HIFU, Osteoma, Prostate cancer, XC2

TULSA-PRO\xc2\xae is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient\xe2\x80\x99s natural functional abilities.

Key Points: 
  • TULSA-PRO\xc2\xae is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient\xe2\x80\x99s natural functional abilities.
  • Sonalleve\xc2\xae has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma.
  • Such statements are based on the current expectations of the management of Profound.
  • Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended.

Profound Medical to Release Fourth Quarter and Full Year 2020 Financial Results on March 2 – Conference Call to Follow

Retrieved on: 
Tuesday, February 9, 2021
Neoplasms, Sonalleve MR-HIFU, Uterine fibroid, Bone metastasis, Clinical medicine, Medicine, Medical ultrasonography, Surgical oncology

Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

Key Points: 
  • Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
  • Profound is commercializing TULSA-PRO, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control.
  • TULSA-PRO is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (FDA).
  • Profound is also commercializing Sonalleve, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

Profound Medical Announces Changes to its Board of Directors

Retrieved on: 
Monday, November 30, 2020
Sonalleve MR-HIFU, Uterine fibroid, Health, Clinical medicine, Medicine

Ms. Lortie is a Chartered Professional Accountant and member of the Ordre des comptables professionnels agres du Qubec.

Key Points: 
  • Ms. Lortie is a Chartered Professional Accountant and member of the Ordre des comptables professionnels agres du Qubec.
  • Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
  • Profound is commercializing TULSA-PRO, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control.
  • Sonallevehas also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids.

Profound Medical Receives FDA HDE Approval for Sonalleve®

Retrieved on: 
Monday, November 30, 2020
HDE, Sonalleve MR-HIFU, Humanitarian Device Exemption, Osteoid osteoma, Food and Drug Administration, Osteoma, Health, Branches of biology

TORONTO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound or the Company) announced today that Sonalleve has received U.S. Food and Drug Administration (FDA) approval under a Humanitarian Device Exemption (HDE) for the treatment of osteoid osteoma.

Key Points: 
  • TORONTO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound or the Company) announced today that Sonalleve has received U.S. Food and Drug Administration (FDA) approval under a Humanitarian Device Exemption (HDE) for the treatment of osteoid osteoma.
  • While we do not expect this FDA HDE approval for Sonalleve to have a material impact on revenues in the near- term, it is nevertheless strategically very important, said Arun Menawat, Profounds CEO and Chairman.
  • Obtaining the first regulatory approval for Sonalleve in the U.S. is a significant milestone for the Company and we are making preparations for the U.S. commercial launch in 2021.
  • Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

Profound Medical to Release Third Quarter 2020 Financial Results on November 5 – Conference Call to Follow

Retrieved on: 
Thursday, October 15, 2020
Sonalleve MR-HIFU, Clinical medicine, Uterine fibroid, Medicine, Magnetic resonance imaging, Ablation, Medical specialties

Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

Key Points: 
  • Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
  • Profound is commercializing TULSA-PRO, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control.
  • TULSA-PRO is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration.
  • Sonalleve has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids.

Profound Medical to Present at the Cantor Virtual Global Healthcare Conference

Retrieved on: 
Wednesday, September 9, 2020
Clinical medicine, Sonalleve MR-HIFU, Medicine, Uterine fibroid, Health, Magnetic resonance imaging, Interventional radiology

The presentation will be broadcast live and archived on the Company's website at www.profoundmedical.com under "Webcasts" in the Investors section.

Key Points: 
  • The presentation will be broadcast live and archived on the Company's website at www.profoundmedical.com under "Webcasts" in the Investors section.
  • Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
  • Profound is commercializing TULSA-PRO, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control.
  • Sonallevehas also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids.

Profound Medical Present at the Canaccord Genuity 40th Annual Growth Conference

Retrieved on: 
Monday, August 10, 2020
Clinical medicine, Sonalleve MR-HIFU, Medicine, Uterine fibroid, Health, Magnetic resonance imaging, Interventional radiology

The presentation will be broadcast live and archived on the Company's website at www.profoundmedical.com under "Webcasts" in the Investors section.

Key Points: 
  • The presentation will be broadcast live and archived on the Company's website at www.profoundmedical.com under "Webcasts" in the Investors section.
  • Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
  • Profound is commercializing TULSA-PRO, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control.
  • Sonallevehas also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids.

Profound Medical to Release Second Quarter 2020 Financial Results on August 6 – Conference Call to Follow

Retrieved on: 
Wednesday, July 22, 2020
Neoplasms, Medicine, Clinical medicine, Gynaecological neoplasia, RTT, Uterine fibroid, Sonalleve MR-HIFU, Bone metastasis, Interventional radiology, High-intensity focused ultrasound

Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

Key Points: 
  • Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
  • Profound is commercializing TULSA-PRO, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control.
  • Profound is also commercializing Sonalleve, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
  • Sonallevehas also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids.